Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF JANUARY 24, 2016 FBO #5175
DOCUMENT

65 -- R&D TGF-beta polyclonal ab - Attachment

Notice Date

1/22/2016
 

Notice Type

Attachment
 

NAICS

339113 — Surgical Appliance and Supplies Manufacturing
 

Contracting Office

Department of Veterans Affairs;Ralph H. Johnson VA Medical Center;109 Bee Street;Charleston SC 29403-5799
 

ZIP Code

29403-5799
 

Solicitation Number

VA24716N0240
 

Response Due

1/29/2016
 

Archive Date

2/28/2016
 

Point of Contact

Dino LaRocca
 

E-Mail Address

Dino.LaRocca@va.gov
(Dino.LaRocca@Va.Gov)
 

Small Business Set-Aside

N/A
 

Description

Sources Sought Notice: TGF-beta Pan Specific Polyclonal Ab For the Ralph H. Johnson VA Medical Center in Charleston, SC. 29401 DESCRIPTION: This is a sources sought to determine the availability of potential sources having the skills and capabilities necessary to provide the SPECIFIED REQUIREMENT. All interested vendors are invited to provide information to contribute to this market survey/sources sought including commercial market information. THIS IS NOT A SOLICITATION ANNOUNCEMENT. This is a sources sought synopsis only. Questions should be submitted by email to Dino.LaRocca@Va.Gov. Provide only the requested information below. The purpose of this synopsis is to gain knowledge of potential qualified sources and their size classifications (Service Disabled/Veteran Owned Small Business (SDVOSB/VOSB), Hub zone, 8(a), small, small disadvantaged, woman owned small business, FSS/GSA contract schedule holders or large business) relative to NAICS 325413, In-Vitro Diagnostic Substance Manufacturing (size standard 500 Employees). Responses to this synopsis will be used by the Government to make appropriate acquisition decisions. After review of the responses to this sources sought synopsis, a solicitation announcement may be published. Responses to this sources sought synopsis are not considered adequate responses to the solicitation announcement. All interested offerors will have to respond to the solicitation announcement in addition to responding to this sources sought announcement. The Government is not obligated to nor will it pay for or reimburse any costs associated with responding to this sources sought synopsis request. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. SPECIFIED REQUIREMENT: Network Contracting Office 7, Charleston, SC is seeking sources for a potential contractor to provide the following: TGF-beta Pan Specific Polyclonal Ab ITEMDESCRIPTIONQTYUNIT 0001AB-100-NA: TGF-BETA PAN SPECIFIC POLYCLONAL AB1EA 0002AB-105-C: NORMAL RABBIT IGG CONTROL1EA STATEMENT OF WORK Purchase of TGF-beta Pan Specific Polyclonal Antibody 11/1/20115 Clinical and Research Utility The main blood vessel exiting the heart, which carries blood to the rest of the body is called the aorta. The aorta is comprised of two continuous segments named for the region of the body that they pass through. The region that runs through the chest is called the thoracic aorta, and the region that runs through the trunk is called the abdominal aorta. Thoracic aortic aneurysm (TAA) is a disease that affects the thoracic aorta causing the vessel wall to weaken and dilate. When the resulting increase in aortic diameter reaches a size equivalent to 1.5x normal, it is called an aneurysm. While the cause of this disease remains unknown, it is clear that when the aortic vessel wall loses its integrity, the risk of it bursting increases. The average age of aneurysm diagnosis is 65 years old, but it is likely that the disease process begins much earlier in life. The disease is very difficult to identify because it rarely has symptoms that are recognized by the patient; a doctor identifies most cases while the patient is being assessed for other issues. Once diagnosed, a "watch and wait" surveillance program is initiated until the risk of the aorta bursting outweighs the risk of the complex surgical repair. Currently, there are no medical therapies designed to reverse or inhibit the changes observed in the aorta with TAA disease. Our research is focused on trying to identify potential treatments for TAA that are aimed at blocking a specific signaling pathway in aortic cells. We believe that this pathway is involved in changing the behavior of a specific cell-type and how it responds to other biological molecules present in the aneurysm. We believe that by studying the changes in the vessel wall, and the changes that the cells undergo during TAA development, the results will help us define new strategies to veterans with TAA disease. One of the ways in which we evaluate aneurysm development and how effective we are at inhibiting aneurysm formation, is through the microscopic analysis of aortic tissue obtained from patients, or experimental animals, with and without aneurysm disease. Accordingly, we would like to purchase a microscope system that will allow us to examine tissue sections for changes in the structure and cellular components of the vessel wall. System Description It is now well accepted that Transforming growth factor-beta (TGF-?) signaling plays an integral role in TAA disease. Our laboratory has proposed several studies that specifically target TGF-? to test the hypothesis that signaling through this pathway plays a significant role in causing a change in cellular phenotype during TAA development. In order to complete these proposals, we have identified a specialized neutralizing TGF-? antibody (TGF-?-NAb; binds TGF-? ligands 1, 2, and 3; R&D Systems, Minneapolis, MN; Cat# AB-100-NA, clone EO20) and a isotype antibody control (Normal Rabbit IgG Control; R&D Systems, Minneapolis, MN; Cat# AB-105-C, clone ER14). the role of TGF-? in TAA development has NEVER been examined outside of MFS. Accordingly, to define the role of TGF-? in non-MFS TAAs, we will deliver the TGF-?-NAb (1 mg/kg, by intraperitoneal injection, every week, starting with TAA induction and continuing until terminal surgery). These studies will test both the role of TGF-? in aortic dilatation, as well as its role in mediating fibroblast transdifferentiation, and they represent an essential piece of knowledge which would allow for the rapid translation to clinical utility. TGF-beta Pan Specific Polyclonal Antibody: Neutralization: Measured by its ability to neutralize TGF beta 1 inhibition of IL 4-dependent proliferation in the HT 2 mouse T cell line. Tsang, M. et al. (1995) Cytokine 7:389. The Neutralization Dose (ND50) is approximately 1 µg/mL, 15 µg/mL, 4 µg/mL, and 1 µg/mL for Porcine TGF-beta 1.2, Porcine TGF-beta 2, Recombinant Chicken TGF-beta 3, and Recombinant Amphibian TGF-beta 5, respectively. The ND50 range for Porcine TGF-beta 1 is 5-30 µg/mL. Overall, this antibody described above, will allow us to complete the studies that were proposed to test both the role of TGF-? in aortic dilatation, as well as its role in mediating fibroblast transdifferentiation. Therefore, the acquisition of this antibody is essential so that we can complete the aims of our funded VA BLR&D project. ~~~END~~~ REQUESTED INFORMATION: (1) STATEMENT OF CAPABILITY: Submit a brief description, ten (10) pages or less that demonstrates how your company has the supervision, facilities, labor and experience to provide the items required. Include past experience in providing these items to the VA, other Government (Federal or State) agency, or for a private facility. Please specify your availability to start date and your address. (2) BUSINESS SIZE AND SOCIO-ECONOMIC STATUS: (a) Indicate whether your business is large or small (b) If small, indicate if your firm qualifies as a small, emerging business, or small disadvantaged business (c) If disadvantaged, specify under which disadvantaged group and if your firm is certified under Section 8(a) of the Small Business Act (d) Indicate if your firm is a certified Hub-zone firm (e) Indicate if your firm is a woman-owned or operated business (f) Indicate if your firm is a certified Service-Disabled Veteran Owned Small Business (SDVOSB) or Veteran Owned Small Business (VOSB) (g) Include the DUNS number of your firm. (h) State whether your firm is registered with the System for Award Management (SAM) at https://www.sam.gov/portal/public/SAM/ and/or the VetBiz Registry at http://vip.vetbiz.gov/. (i) If not, please NOTE that any future solicitation could only be awarded to a contractor who is registered in SAM and to receive award based on VOSB or SDVOSB status you must be registered in the VetBiz Registry. If the requirement is available on your GSA, FSS or GWAC schedule include the schedule number and associated SINs. Responses must be emailed to Dino.LaRocca@Va.Gov no later than 3PM EDT on Wednesday, January 27, 2016. Your response should include both the STATEMENT OF CAPABILITY and BUSINESS SIZE AND SOCIO-ECONOMIC STATUS information as explained above. Please place "VA247-16-N-0240 TGF-beta Pan Specific Polyclonal Ab" in the subject line of your email. This notice is to assist the VA in determining sources only. A SOLICITATION IS NOT CURRENTLY AVAILABLE. If a solicitation is issued it will be announced at a later date, and all interested parties must respond to that solicitation announcement separately from the responses to this announcement.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/VA/ChaVAMC/VAMCCO80220/VA24716N0240/listing.html)
 

Document(s)

Attachment
 

File Name: VA247-16-N-0240 VA247-16-N-0240.docx (https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=2521515&FileName=VA247-16-N-0240-000.docx)

Link: https://www.vendorportal.ecms.va.gov/FBODocumentServer/DocumentServer.aspx?DocumentId=2521515&FileName=VA247-16-N-0240-000.docx

 

Note: If links are broken, refer to Point of Contact above or contact the FBO Help Desk at 877-472-3779.
 

Record

SN03998479-W 20160124/160122233646-cf1d7b2246a5b053a98f5a141c715c6f (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |